AstraZeneca has published a technical note describing its internal LLM-based system, Research Assistant, which is now deployed at scale to support scientists and clinicians in their day-to-day R&D workflows. This is not a research experiment — it's a production system that brings together evidence from scientific literature, knowledge graphs, chemistry, clinical trials, safety resources, expression data, and internal experimental systems into a single chat-style interface. The technical note on arXiv outlines the architecture and design choices behind the product.
The system offers two modes: a fast mode for direct question answering and a multi-step mode for more complex research tasks. Responses are grounded in retrieved evidence and linked back to original sources, allowing users to review and explore the underlying data. This grounding is critical for a regulated industry where trust and traceability are non-negotiable.
For decision-makers, the significance is strategic. AstraZeneca is showing that agentic AI systems can be built and deployed in a heavily regulated, high-stakes environment — and that they can deliver value across a broad range of data sources. The lessons learned from this deployment are directly relevant for any organization considering similar investments in AI for R&D, whether in pharma, biotech, or other knowledge-intensive sectors.
The paper also signals a shift: AI is no longer just a tool for individual researchers, but a platform that integrates into core workflows. As more companies follow this path, the competitive advantage will likely shift to those who can effectively integrate AI into their existing data ecosystems and processes.
